As venture capitalist: Founder and CEO of Quantica SGR, Founder and Investment Manager of Axòn Capital, Venture Consultant at Sofinnova Partners and Venture Partner at AurorA Science; Investor and Board Director at EOS – Ethical Oncology Science. Member of the Assobiotec Steering Committee; Member of the ItaliaStartup Board; Board Member at Altheia Science; Member of the Life Sciences Technical Group at Confindustria
Executive Partner with OrbiMed. Co-founder of Alexion Pharmaceuticals, CEO of Passage Bio, various senior leadership positions at Regeneron Pharmaceuticals. Brings over 25 years of biotechnology industry experience
McKinsey & Company emeritus director and former board member at Luxottica (NYSE:LUX), COFIDE (IT:COF), Teva (NYSE: TEVA), and Admiral (LSE: ADM). Chairman of the INSEAD’s advisory group in Italy.
35 years at global top positions in big pharmaceuticals at all levels; managed staff up to 7,000 employees with turnover over 7B€; former Head of Pharma EU at Novartis, previously Head of Oncology at Novartis EU (drugs: Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge and others)
Deputy Scientific Director, OSR - San Raffaele Hospital, Milano, Italy; Adjunct Member, Department of Immunology & Microbial Sciences, The Scripps Research Institute (TSRI), La Jolla, California, USA; Full Professor of General Pathology, UniSR, Medical School, Milano; Head, Immunopathology Unit, OSR, Milano, Italy.
As Head of Business Development at San Raffaele Hospital she oversees the technology transfer office and other functions of technology development and valorisation of San Raffaele’s research outputs in the field of biotech, med tech and digital health. Board Member of San Raffaele’s spin off Genespire (as observer). She has been Board Member at Parco Tecnologico Padano and Board Member Observer of BiovelocITA as well as Advisor to several life science start-up companies, venture capital, and incubators in the biotech and med tech field. Previous experience includes: founder and managing director of TTFactor, the former joint tech transfer company of the European Institute of Oncology (IEO) and the Firc Institute for Molecular Oncology (IFOM).